Department of Radiology, University of Insubria, Viale Borri 57, Varese 21100, Italy.
Cardiovasc Intervent Radiol. 2010 Apr;33(2):367-74. doi: 10.1007/s00270-009-9745-x. Epub 2009 Nov 14.
The purpose of this study was to determine the safety, effectiveness, and feasibility of microwave ablation (MWA) of small renal cell carcinomas (RCCs) in selected patients. Institutional review board and informed consent were obtained. From December 2007 to January 2009, 12 patients (8 male, 4 female) were enrolled in a treatment group, in which percutaneous MWA of small RCCs was performed under contrast-enhanced ultrasound guidance. The tumors were 1.7-2.9 cm in diameter (mean diameter, 2.0 cm).Therapeutic effects were assessed at follow-up with computed tomography. All patients were followed up for 3-14 months (mean, 6 months) to observe the therapeutic effects and complications (according to SIR classification). Assessment was carried out with CT imaging. No severe complications or unexpected side effects were observed after the MWA procedures. In all cases technical success was achieved. Clinical effectiveness was 100%; none of the patients showed recurrence on imaging. In conclusion, our preliminary results support the use of MWA for the treatment of small renal tumors. This technology can be applied in select patients who are not candidates for surgery, as an alternative to other ablative techniques.
本研究旨在确定在选定患者中，微波消融（MWA）治疗小肾细胞癌（RCC）的安全性、有效性和可行性。本研究获得了机构审查委员会和知情同意书。2007 年 12 月至 2009 年 1 月，12 名患者（8 名男性，4 名女性）被纳入治疗组，在增强超声引导下进行经皮 MWA 治疗小 RCC。肿瘤直径为 1.7-2.9cm（平均直径 2.0cm）。在随访时使用计算机断层扫描评估治疗效果。所有患者均随访 3-14 个月（平均 6 个月），以观察治疗效果和并发症（根据 SIR 分类）。采用 CT 成像进行评估。在 MWA 手术后，未观察到严重并发症或意外副作用。在所有情况下均实现了技术成功。临床疗效为 100%；影像学检查未见任何患者复发。总之，我们的初步结果支持将 MWA 用于治疗小肾肿瘤。对于不适合手术的患者，该技术可以作为其他消融技术的替代方法。
